Purchase Order 75N91020P00259

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $20,283.34 on April 24, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland. The order is set to complete by July 19, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $12,560.00 on February 22, 2021, for a service agreement with a firm fixed price structure and no set-aside designation. Performance is located in Bethesda, Maryland, with an ultimate completion date of April 30, 2021.</p>

<p>The National Cancer Institute issued a $13,043.75 delivery order to Illumina, Inc. on August 17, 2018, for genetic sequencing and genomic analysis technologies.</p> <p>Place of performance is Bethesda, MD. The order has a firm fixed-price pricing structure and an ultimate completion date of September 15, 2018. Illumina manufactures advanced DNA and RNA sequencing instruments, reagents, consumables, and bioinformatics software supporting genomic research across federal agencies.</p>

<p>The National Cancer Institute issued a $17,792.10 delivery order to Illumina, Inc. on January 13, 2020, for reagents and consumables.</p> <p>Place of performance is Bethesda, MD 20892. Ultimate completion date is February 12, 2020. The order is firm fixed price with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $24,158.08 on October 19, 2017, with an ultimate completion date of November 19, 2018. Performance occurs at Bethesda, Maryland. The order is firm fixed price with no set-aside designation. Specific requirements are not detailed in the source material.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on June 26, 2018, with a ceiling value of $13,043.75 and an ultimate completion date of July 26, 2018.</p> <p>Place of performance is Bethesda, MD 20892. The order is priced on a firm fixed-price basis with no set-aside designation. The delivery order procures genetic sequencing equipment, reagents, consumables, or related bioinformatics services from Illumina's portfolio of genomic analysis technologies.</p>

<p>The National Cancer Institute issued a delivery order to Illumina, Inc. on September 7, 2017, with a ceiling value of $6,700.18.</p> <p>Place of performance is Bethesda, MD 20892. The order has a firm fixed-price structure and an ultimate completion date of October 8, 2017. The delivery order calls for genetic sequencing equipment, reagents, consumables, or bioinformatics software consistent with Illumina's portfolio of DNA and RNA sequencing instruments and analytical tools.</p>

<p>The National Cancer Institute issued a $5,217.50 delivery order to Illumina, Inc. on February 8, 2018, with an ultimate completion date of March 10, 2018.</p> <p>Place of performance is Bethesda, MD 20892. The order is priced on a firm fixed-price basis with no set-aside designation. The source does not identify the parent vehicle under which this delivery order was issued.</p>

<p>The National Cancer Institute issued a $13,043.75 delivery order to Illumina, Inc. on June 20, 2018, for genetic sequencing and genomic analysis technologies. Place of performance is Bethesda, MD. Ultimate completion date is July 19, 2018.</p> <p>The source does not identify the parent vehicle under which this delivery order was issued.</p>

<p>The National Cancer Institute issued a $3,598.76 delivery order to Illumina, Inc. on January 24, 2018, for materials for project, with final completion scheduled for February 18, 2018.</p> <p>Place of performance is Bethesda, MD 20892. The order is priced firm fixed-price with no set-aside designation.</p>